Cibiyar Cleveland Clinic ta Amurka Eric D. His et al. Ya ruwaito cewa ganewar asali na kwayar halitta ta kwayar halitta ta kwayar halitta (PTCL) a Amurka ta bambanta sosai, kuma galibi ba shi da wani muhimmin bayani game da kwayar cutar ta lymphoma. Idan akai la'akari da rabe-raben Kungiyar Kiwon Lafiya ta Duniya mai zuwa, ya kamata a cike rarar gwajin ga alamun da aka zaba. Cikakken bincike na yau da kullun yana da mahimmanci, zai kawo mu cikin zamanin maganin farfaɗo na PTCL. (Clin Lymphoma Myeloma Leuk. 2017; 17: 193-200.)
Tare da zurfafa fahimtar keɓaɓɓun yawan mutanen yankin T-cell lymphoma (PTCL), hanyoyin bincike na ƙayyadaddun ƙwayoyi suna ci gaba da fitowa, kuma cikakken bincike na asali yana da mahimmanci.
Nazarin ya samo bayanai daga nazarin cikakkun matakan kulawa don ƙananan ƙwayoyin T-cell lymphoma (KAMMALA) kuma ya gudanar da nazarin hanyoyin marasa lafiya tare da ganewar asusu na PTCL. Cikakken binciken shine babban binciken ƙungiyar masu haƙuri tare da sabon PTCL a cikin Amurka. Sakamakon ya nuna cewa marasa lafiya 499 sun shiga daga cibiyoyin ilimi 40 da cibiyoyin al'umma 15. An tattara nau'in kimantawa na asali a cikin shari'o'in 493, wanda 435 (88%) suka kasance don bincike. Mafi yawan cututtukan cututtuka sune PTCL, PTCL da ba'a bayyana ba (PTCL-NOS), babban kwayar maganin ƙwayar cuta da kuma kwayar cutar kwayar cutar T cell ta angioimmunoblastic (AITL). Kowane mai haƙuri ya kimanta alamun 10 (0-21). CD30 ana yin la'akari akai-akai, amma bayanin CD30 bai dace da marasa lafiya waɗanda ba su da babban kwayar cutar kwayar halitta ba. Kawai 17% na marasa lafiya tare da PTCL-NOS sun kimanta bayanin PD1. CXCL13 shine mai nuna alamun AITL. Adadin nunawa na marasa lafiyar AITL shine 84%, amma 3% na marasa lafiyar PTCL-NOS sun gano maganganun CXCL13. Sakamakon kimantawa na alamomin taimakon kwayar halitta T mai nuna bambanci ya bambanta tsakanin marasa lafiya a cibiyoyin ilimi da al'ummomi. Cibiyoyin Ilimi suna yawan nazarin maganganun PD1 a cikin marasa lafiya tare da AITL (62% vs 12%, P = 0.01).
